Novartis AG
NVSEF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $51,722,000 | $46,660,000 | $51,828,000 | $52,877,000 |
| % Growth | 10.8% | -10% | -2% | – |
| Cost of Goods Sold | $12,827,000 | $12,020,000 | $15,486,000 | $15,867,000 |
| Gross Profit | $38,895,000 | $34,640,000 | $36,342,000 | $37,010,000 |
| % Margin | 75.2% | 74.2% | 70.1% | 70% |
| R&D Expenses | $10,022,000 | $11,371,000 | $9,996,000 | $9,540,000 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $12,566,000 | $12,489,000 | $14,253,000 | $14,886,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1,763,000 | $1,011,000 | -$101,215 | $269,572 |
| Operating Expenses | $24,351,000 | $24,871,000 | $27,145,000 | $25,321,000 |
| Operating Income | $14,544,000 | $9,769,000 | $9,197,000 | $11,689,000 |
| % Margin | 28.1% | 20.9% | 17.7% | 22.1% |
| Other Income/Exp. Net | -$904,000 | -$646,000 | $425,000 | $13,335,000 |
| Pre-Tax Income | $13,640,000 | $9,123,000 | $8,371,000 | $25,024,000 |
| Tax Expense | $1,701,000 | $551,000 | $1,416,000 | $2,119,000 |
| Net Income | $11,941,000 | $14,850,000 | $6,955,000 | $24,021,000 |
| % Margin | 23.1% | 31.8% | 13.4% | 45.4% |
| EPS | 5.92 | 7.63 | 3.29 | 10.73 |
| % Growth | -22.4% | 131.9% | -69.3% | – |
| EPS Diluted | 5.87 | 7.58 | 3.27 | 10.65 |
| Weighted Avg Shares Out | 2,018,000 | 2,076,794 | 2,181,180 | 2,242,601 |
| Weighted Avg Shares Out Dil | 2,035,000 | 2,092,000 | 2,197,000 | 2,260,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $550,781 | $436,000 | $389,368 | $71,151 |
| Interest Expense | $1,005,564 | $855,000 | $860,329 | $906,925 |
| Depreciation & Amortization | $6,069,000 | $8,834,577 | $6,924,974 | $5,440,550 |
| EBITDA | $20,715,000 | $19,517,830 | $15,209,122 | $17,168,447 |
| % Margin | 40.1% | 41.8% | 29.3% | 32.5% |